NBIX

Neurocrine Biosciences, Inc.

134.36 USD
-0.22 (-0.16%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Neurocrine Biosciences, Inc. stock is down -3.62% since 30 days ago. The next earnings date is Jul 30, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 48.28% of the previous 28 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 2 PUTs, 8 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
31 May 15:00 21 Mar, 2025 125.00 PUT 83 0
05 Jun 14:23 15 Nov, 2024 140.00 CALL 22 3
05 Jun 14:29 15 Nov, 2024 140.00 CALL 43 3
05 Jun 14:32 15 Nov, 2024 140.00 CALL 20 3
06 Jun 15:40 20 Sep, 2024 140.00 CALL 29 141
12 Jun 19:56 20 Sep, 2024 145.00 CALL 32 62
17 Jun 19:54 20 Dec, 2024 130.00 CALL 15 56
18 Jun 13:56 19 Jul, 2024 125.00 PUT 734 1004
18 Jun 14:11 20 Sep, 2024 150.00 CALL 119 106
21 Jun 15:29 16 Aug, 2024 145.00 CALL 168 64

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. Company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease.

  • Morgan Stanley
    Wed Jun 12, 13:02
    buy
    confirm
  • Wedbush
    Wed May 29, 08:30
    buy
    confirm
  • UBS
    Tue May 28, 08:06
    buy
    confirm